

Effective: September 1, 2023

<p>Prior Authorization Required If <u>REQUIRED</u>, submit supporting clinical documentation pertinent to service request to the FAX numbers below</p>	Yes <input type="checkbox"/> No <input checked="" type="checkbox"/>
<p>Notification Required IF <u>REQUIRED</u>, concurrent review may apply</p>	Yes <input type="checkbox"/> No <input checked="" type="checkbox"/>

Applies to:

Commercial Products

- Harvard Pilgrim Health Care Commercial products; 800-232-0816
- Tufts Health Plan Commercial products; 617-972-9409
CareLinkSM – Refer to CareLink Procedures, Services and Items Requiring Prior Authorization

Public Plans Products

- Tufts Health Direct – A Massachusetts Qualified Health Plan (QHP) (a commercial product); 888-415-9055
- Tufts Health Together – MassHealth MCO Plan and Accountable Care Partnership Plans; 888-415-9055
- Tufts Health RITogether – A Rhode Island Medicaid Plan; 857-304-6404
- Tufts Health Unify* – OneCare Plan (a dual-eligible product); 857-304-6304
*The MNG applies to Tufts Health Unify members unless a less restrictive LCD or NCD exists.

Senior Products

- Harvard Pilgrim Health Care Stride Medicare Advantage; 866-874-0857
- Tufts Health Plan Senior Care Options (SCO), (a dual-eligible product); 617-673-0965
- Tufts Medicare Preferred HMO, (a Medicare Advantage product); 617-673-0965
- Tufts Medicare Preferred PPO, (a Medicare Advantage product); 617-673-0965

Note: While you may not be the provider responsible for obtaining prior authorization or notifying Point32Health, as a condition of payment you will need to ensure that any necessary prior authorization has been obtained and/or Point32Health has received proper notification. If notification is required, providers may additionally be required to provide updated clinical information to qualify for continued service.

Overview

Allergy is a form of hypersensitivity or reactivity of the immune system, to a particular external substance following exposure. This can occur in response to substances that are inhaled, swallowed, injected, or by contact with the skin or eyes. These substances can vary by individual, but commons ones include dust, mold, animal dander and pollen.

Allergy testing can be broadly subdivided into two methodologies:

- In vivo testing – includes skin allergy testing (i.e., skin prick testing, skin scratch testing, intradermal testing, skin patch testing, and skin endpoint titration), bronchial provocation tests, and food challenges
- In vitro testing – identifies the presence of allergen-specific immunoglobulin E (IgE) in the blood serum. These tests may be used for inhalant allergens (e.g., pollen, mold, dander, or dust), foods, insect stings for younger children or when direct skin testing is impossible due to extensive dermatitis, or dermatographism or conditions where antihistamines cannot be stopped for skin testing, such as chronic hives.

Allergy immunotherapy is the process of administering progressively increasing doses of an allergen as treatment for a person who has demonstrated sensitivity through allergy testing. Immunotherapy for allergic diseases involves gradual administration and introduction of allergens to which the individual is sensitive to, for the purpose of modulating an immune response and alleviating allergic symptoms.

Clinical Guideline Coverage Criteria

Allergy Testing

The Plan considers allergy testing as reasonable and medically necessary when **ONE** following are met:

1. Percutaneous Tests when documentation confirms testing is required for reaction to **ONE** of the following:
 - a. Inhalants; **or**
 - b. Foods where individuals present signs or symptoms of urticarial, angioedema, eosinophilic esophagitis, or anaphylaxis after ingestion of specific foods; **or**
 - c. Hymenoptera; **or**
 - d. Specific drugs (e.g., penicillin, macromolecular agents, enzymes, egg-containing vaccines)
2. Intracutaneous/Intradermal Tests when documentation confirms percutaneous tests are negative and there is suspected allergen sensitivity to **ONE** of the following:
 - a. Inhalants; **or**
 - b. Hymenoptera; **or**
 - c. Specific drugs (e.g., penicillin, macromolecular agents); **or**
 - d. Vaccines
3. Patch Tests when documentation confirms the test will be utilized to diagnose allergic contact dermatitis after **ONE** of the following exposures:
 - a. Dermatitis due to detergents; **or**
 - b. Oils and greases; **or**
 - c. Solvents, drugs, and medicines in contact with skin; **or**
 - d. Food in contact with skin; **or**
 - e. Plants; **or**
 - f. Cosmetics; **or**
 - g. Metals or rubber additives
4. Photo Patch Testing to diagnose suspected allergies resulting from light exposure (e.g., photo-allergic contact dermatitis); **or**
5. Photo Tests to evaluate photo-sensitivity disorders; **or**
6. Delayed Hypersensitivity Skin Testing for allergen testing, testing for infection with intracellular pathogens, or testing for sensitivity to contact allergens; **or**
7. Ingestion (Oral) Challenge Test when documentation confirms **ONE** of the following:
 - a. Food allergy dermatitis; **or**
 - b. Anaphylactic shock due to adverse food reaction; **or**
 - c. Allergy to medicinal agents; **or**
 - d. Allergy to foods; **or**
8. Allergy has resolved or has been disproven; **or**
9. In Vitro Allergy Testing when skin testing is not possible, and documentation confirms **ANY** of the following criteria:
 - a. Individual has a skin condition that will not make direct skin testing possible; **or**
 - b. Individual requires continued use of H-1 blockers (antihistamines), or in the rare patient with persistent unexplained negative histamine control; **or**
 - c. Individual cannot be safely withdrawn from medications that interfere with skin testing; **or**
 - d. Testing is difficult due to mental or physical impairments; **or**
 - e. To evaluate cross-reactivity between insect venoms (e.g., fire ant, bee, wasp, yellow jacket, hornet) ; **or**
 - f. To utilize for adjunctive laboratory testing for disease activity of allergic bronchopulmonary aspergillosis and certain parasitic disease; **or**
 - g. To diagnose atopy in small children; **or**
 - h. Individual is at increased risk for anaphylactic response from skin testing based on clinical history; **or** who has a history of a previous systemic reaction to skin testing; **or**
 - i. Skin testing was inconclusive and in vitro testing is required as a confirmatory test.

Exclusions: The Plan considers allergen testing as not medically necessary for all other indications. In addition, The Plan does not cover:

1. Serum IgG testing or IgG subclass testing for any specific allergens
2. IgE testing at home

Allergen Immunotherapy

1. The Plan considers allergen immunotherapy as reasonable and medically necessary when administered under the supervision of an appropriately trained physician and when documentation confirms **ONE** of the following:
2. Diagnosis of Allergic Asthma, Allergic Conjunctivitis, Allergic Rhinitis, or Stinging Insect Hypersensitivity when **ALL** of the following are met:

- a. Results of allergy testing show immediate hypersensitivity to skin tests or in vitro tests for specific immunoglobulin E (IgE); **and**
 - b. Contraindication to or failed maintenance by pharmacologic therapy; **and**
 - c. Individual's treatment plan, dosage and immunotherapy schedule, antigens to be administered, and target maintenance dose for allergy immunotherapy.
3. Stinging Insect Immunotherapy when **ALL** of the following are met:
 - a. Diagnosis of anaphylaxis after an insect sting or hives alone in children under 16 years of age; **and**
 - b. Positive skin test or other documented IgE sensitivity to specific stinging insect venom
 4. Allergy Immunotherapy for the **ONE** of the following
 - a. Animal dander sensitivity (epidermal) when documentation confirms antihistamines do not relieve symptoms; **or**
 - b. Standardized dust mite extracts or perennials such as cat and dog dander and cockroach; **or**
 - c. Delayed systemic reactions with symptoms of anaphylaxis with a positive skin test or presence of venom specific IgE; **or**
 - d. Rapid desensitization for cases of allergy to insulin, penicillin, sulfonamides, cephalosporins and other commonly used drugs

Codes

The following code(s) are associated with this service:

Table 1: CPT/HCPCS Codes – Allergy Testing Codes

Code	Description
82785	Gammaglobulin (immunoglobulin); IgE
86003	Allergen specific IgE; quantitative or semiquantitative, crude allergen extract, each
86008	Allergen specific IgE; quantitative or semiquantitative, recombinant or purified component, each
95004	Percutaneous tests (scratch, puncture, prick) with allergenic extracts, immediate type reaction, including test interpretation and report, specify number of tests
95017	Allergy testing, any combination of percutaneous (scratch, puncture, prick) and intracutaneous (intradermal), sequential and incremental, with venoms, immediate type reaction, including test interpretation and report, specify number of tests
95018	Allergy testing, any combination of percutaneous (scratch, puncture, prick) and intracutaneous (intradermal), sequential and incremental, with drugs or biologicals, immediate type reaction, including test interpretation and report, specify number of tests
95024	Intracutaneous (intradermal) tests with allergenic extracts, immediate type reaction, including test interpretation and report, specify number of tests
95027	Intracutaneous (intradermal) tests, sequential and incremental, with allergenic extracts for airborne allergens, immediate type reaction, including test interpretation and report, specify number of tests
95028	Intracutaneous (intradermal) tests with allergenic extracts, delayed type reaction, including reading, specify number of tests
95044	Patch or application test(s) (specify number of tests)
95052	Photo patch test(s) (specify number of tests)
95056	Photo tests
95070	Inhalation bronchial challenge testing (not including necessary pulmonary function tests); with histamine, methacholine, or similar compounds
95076	Ingestion challenge test (sequential and incremental ingestion of test items, e.g., food, drug or other substance); initial 120 minutes of testing
95079	Ingestion challenge test (sequential and incremental ingestion of test items, e.g., food, drug or other substance); each additional 60 minutes of testing

Table 2: CPT/HCPCS Codes – Allergy Immunotherapy Codes

Codes	Description
95115	Professional services for allergen immunotherapy not including provision of allergenic extracts; single injection
95117	Professional services for allergen immunotherapy not including provision of allergenic extracts; 2 or more injections

Codes	Description
95144	Professional services for the supervision of preparation and provision of antigens for allergen immunotherapy, single dose vial(s) (specify number of vials)
95145	Professional services for the supervision of preparation and provision of antigens for allergen immunotherapy (specify number of doses); single stinging insect venom
95146	Professional services for the supervision of preparation and provision of antigens for allergen immunotherapy (specify number of doses); 2 single stinging insect venoms
95147	Professional services for the supervision of preparation and provision of antigens for allergen immunotherapy (specify number of doses); 3 single stinging insect venoms
95148	Professional services for the supervision of preparation and provision of antigens for allergen immunotherapy (specify number of doses); 4 single stinging insect venoms
95149	Professional services for the supervision of preparation and provision of antigens for allergen immunotherapy (specify number of doses); 5 single stinging insect venoms
95165	Professional services for the supervision of preparation and provision of antigens for allergen immunotherapy; single or multiple antigens (specify number of doses)
95170	Professional services for the supervision of preparation and provision of antigens for allergen immunotherapy; whole body extract of biting insect or other arthropod (specify number of doses)
95180	Rapid desensitization procedure, each hour (e.g., insulin, penicillin, equine serum)

List of Medically Necessary ICD-10 Codes – Allergy Testing: [Harvard Pilgrim](#) and [Tufts Health Plan](#)

List of Medically Necessary ICD-10 Codes – Allergy Immunotherapy: [Harvard Pilgrim](#) and [Tufts Health Plan](#)

References:

1. Abramson, Michael J, Puy, Robert M, Weiner, John M. Injection allergen immunotherapy for asthma. Cochrane Database of Systematic Reviews 2010, Issue 8. Art. No.: CD001186. DOI: 10.1002/14651858.CD001186.pub2.
2. Allergy Diagnostic Testing: An Updated Practice Parameter. American Academy of Allergy, Asthma and Immunology. 2008. Available at: <http://www.aaaai.org/Aaaai/media/MediaLibrary/PDF%20Documents/Practice%20and%20Parameters/allergydiagnostictesting.pdf>. Accessed February 3, 2021.
3. Allergy Immunotherapy (L28451). 2011. Available at: https://apps.ngsmedicare.com/lcd/LCD_L28451.htm. Accessed February 3, 2021.
4. Allergy Testing for Diagnosis of Respiratory Allergy, In Vitro. Hayesinc.com/login [via subscription only]. Accessed February 3, 2021.
5. Allergy Testing for Diagnosis of Respiratory Allergy, In Vitro. Hayesinc.com/login [via subscription only]. Accessed February 3, 2021.
6. Allergy Testing, In Vivo. Hayesinc.com/login [via subscription only]. Accessed January 20, 2020.
7. Bae, JM., Choi, YY., Park, CO., Chung, KY., Lee, KH. Efficacy of allergen-specific immunotherapy for atopic dermatitis: a systematic review and meta-analysis of randomized controlled trials. J Allergy Clin Immunol. 2013; 132(1): 110-7.
8. Bahceclier, NN., Galip, N. Comparing subcutaneous and sublingual immunotherapy: what do we know? Curr Opin Allergy Clin Immunol. 2012; 12(6): 640-7.
9. Bernstein, IL., Li, JT., Bernstein, DI., et al. Allergy diagnostic testing: an updated practice parameter. Ann Allergy Asthma Immunol. 2008; 100(3 Supple 3): S1-148.
10. Bousquet J, Lockey R, Malling HJ, et al. Allergen immunotherapy: therapeutic vaccines for allergic diseases. World Health Organization. American academy of Allergy, Asthma and Immunology. Ann Allergy Asthma Immunol 1998; 81: 401-5.
11. Boyle, Robert J, Elremeli, Mariam, Hockenull, Juliet, Cherry, Mary Gemma, Bulsara, Max K, Daniels, Michael, Oude Elberink, J.N.G.. Venom immunotherapy for preventing allergic reactions to insect stings. Cochrane Database of Systematic Reviews 2012, Issue 10. Art. No.: CD008838. DOI: 10.1002/14651858.CD008838.pub2.
12. Brown SG, Hass MA, Black JA, Parameswaran A, Woods GM, Heddle RJ. In vitro testing to diagnose venom allergy and monitor immunotherapy: a placebo-controlled, crossover trial. Clin Exp Allergy. 2004 May; 34(5): 792-800. Accessed February 3, 2021.
13. Calderon, Moises A, Alves, Bernadette, Jacobson, Mikila, Hurwitz, Brian, Sheikh, Aziz, Durham, Stephen. Allergen injection immunotherapy for seasonal allergic rhinitis. Cochrane Database of Systematic Reviews 2007, Issue 1. Art. No.: CD001936. DOI: 10.1002/14651858.CD001936.pub2.
14. Calderon, Moises A, Carr, Vicky A, Jacobson, Mikila, Sheikh, Aziz, Durham, Stephen. Allergen injection immunotherapy for perennial allergic rhinitis. (Protocol) Cochrane Database of Systematic Reviews 2008, Issue 2. Art. No.: CD007163. DOI: 10.1002/14651858.CD007163.

15. Cappella, A., Durham, SR. Allergen immunotherapy for allergic respiratory diseases. *Hum Vaccin Immunother.* 2012; 8(10): 1499-512.
16. Clinical Care Statements. American Academy of Otolaryngic Allergy (AAOA); 2015. Available at: http://www.aoaallergy.org/wp-content/uploads/2017/05/2015.Clinical-Care-Statements-Bro.web_.pdf. Accessed February 3, 2021.
17. Cox L, Nelson H, Lockey R et al. Allergen immunotherapy: A practice parameter third update. *Journal of Allergy and Clinical Immunology.* 2011;127(1):S1-S55. doi:10.1016/j.jaci.2010.09.034.
18. Dretzke, J., Meadows, A., Novielli, N., et al. Subcutaneous and sublingual immunotherapy for seasonal allergic rhinitis: a systematic review and indirect comparison. *J Allergy Clin Immunol.* 2013; 131(5): 1361-6.
19. Esch, RE., Plunkett, GA. Immunotherapy preparation guidelines, rules and regulation. *Curr Allergy Asthma rep.* 2013; 13(4): 406-13.
20. Golden, DB., Lawrence, ID., Hamilton, RH., et al. Clinical correlation of the venom-specific IgG antibody level during maintenance venom immunotherapy. *J Allergy Clin Immunol.* 1992; 90(3 Pt 1): 386-93.
21. Hymenoptera venom immunotherapy: Efficacy, indications, and mechanisms of action. [UpToDate.com/login](https://www.uptodate.com/lookup/login) [via subscription only]. Accessed February 3, 2021.
22. Klimek, L., Pfaar, O. A comparison of immunotherapy delivery methods for allergen immunotherapy. *Expert Rev Clin Immunol.* 2013; 9(5): 465-74.
23. Krouse JH, Mabry RL. Skin testing for inhalant allergy 2003: Current strategies. *Otolaryngol Head Neck Surg.* 2003;129 (Suppl 4):S33-S49.
24. Lavine, E. Blood testing for sensitivity, allergy or intolerance to food. *CMAJ.* 2012; 184(6): 666-8.
25. Li J. Allergy Testing. American Academy of Family Physicians. 2002. Available at: <https://www.aafp.org/afp/2002/0815/p621.html>. Accessed February 3, 2021.
26. Ligaarden, SC., Lydersen, S., Farup, PG. IgG and IgG4 antibodies in subjects with irritable bowel syndrome: a case control. Study in the general population. *BMC Gastroenterol.* 2012 Nov 21.
27. Lin, SY., Erekosima, N., Kim, JM., et al. Sublingual immunotherapy for the treatment of allergic rhinoconjunctivitis and asthma: a systematic review. *JAMA.* 2013; 309(12): 1278-88.
28. Local Coverage Determination (LCD): Allergy Testing (L36402). Centers for Medicare and Medicaid Services (CMS). Accessed November 30, 2022.
29. Local Coverage Determination (LCD): Allergy Immunotherapy (L36408). Centers for Medicare and Medicaid Services (CMS). Accessed November 30, 2022.
30. Local Coverage Article: Billing and Coding: Allergy Testing (A57473). Centers for Medicare and Medicaid Services (CMS). Accessed November 30, 2022.
31. Local Coverage Article: Billing and Coding: Allergy Immunotherapy (A57472). Centers for Medicare and Medicaid Services (CMS). Accessed February 3, 2021.
32. Muller, UR. Bee venom allergy in beekeepers and their family members. *Curr Opin Allergy Clin Immunol.* 2005; 5(4): 343-7.
33. Overview of immunologic treatments for allergic rhinitis. [UpToDate.com/login](https://www.uptodate.com/lookup/login) [via subscription only]. Accessed February 3, 2021.
34. Overview of In Vitro Allergy Tests. [Hayesinc.com/login](https://www.hayesinc.com/lookup/login) [via subscription only]. Accessed February 3, 2021.
35. Overview of In Vitro Allergy Tests. [UpToDate.com/login](https://www.uptodate.com/lookup/login) [via subscription only]. Accessed February 3, 2021.
36. Philpott, H., Nandurkar, S., Lubel, J., Gibson, PR. Alternative investigations for irritable bowel syndrome. *J Gastroenterol Hepatol.* 2013; 28(1): 73-7.
37. Physical properties, genetics, and biologic functions. [UpToDate.com/login](https://www.uptodate.com/lookup/login) [via subscription only]. Accessed February 3, 2021.
38. Reisman, RE. Should routine measurements of serum venom-specific IgG be a standard of practice in patients receiving venom immunotherapy? *J Allergy Clin Immunol.* 1992; 90(3 Pt 1): 282-4.
39. Ross RN, Nelson HS, Finegold I. Effectiveness of specific immunotherapy in the treatment of allergic rhinitis: an analysis of randomized, prospective, single- or double-blind, placebo-controlled studies. *Clin Ther* 2000; 22:342-50.
40. Simola M, Malmberg H. Nasal histamine reactivity; relationships to skin-test responses, allergen provocation and symptom severity in patients with long-continuing allergic rhinitis. *Acta Otolaryngol.* 2000 Jan; 12D(1): 67-71. Accessed February 3, 2021.
41. Subcutaneous immunotherapy for allergic disease: Indications and efficacy. [UpToDate.com/login](https://www.uptodate.com/lookup/login) [via subscription only]. Accessed February 3, 2021.
42. Sublingual and oral immunotherapy for allergic rhinitis. [UpToDate.com/login](https://www.uptodate.com/lookup/login) [via subscription only]. Accessed February 3, 2021.
43. Wilson, AB., Deighton, J., Lackman, PJ., Ewan, PW. A comparative study of IgG subclass antibodies in patients

allergic to wasp or bee venom. Allergy. 1994; 49(4).

Approval And Revision History

December 1, 2022: Reviewed by the Medical Policy Approval Committee (MPAC) for integration between Harvard Pilgrim Health Care and Tufts Health Plan for effective date June 1, 2023. Medical necessity edit established for Tufts Health Plan, criteria and limitations clarified.

Subsequent endorsement date(s) and changes made:

- June 21, 2023: Reviewed by MPAC; renewed without changes

Background, Product and Disclaimer Information

Medical Necessity Guidelines are developed to determine coverage for benefits and are published to provide a better understanding of the basis upon which coverage decisions are made. We make coverage decisions using these guidelines, along with the Member's benefit document, and in coordination with the Member's physician(s) on a case-by-case basis considering the individual Member's health care needs.

Medical Necessity Guidelines are developed for selected therapeutic or diagnostic services found to be safe and proven effective in a limited, defined population of patients or clinical circumstances. They include concise clinical coverage criteria based on current literature review, consultation with practicing physicians in our service area who are medical experts in the particular field, FDA and other government agency policies, and standards adopted by national accreditation organizations. We revise and update Medical Necessity Guidelines annually, or more frequently if new evidence becomes available that suggests needed revisions.

For self-insured plans, coverage may vary depending on the terms of the benefit document. If a discrepancy exists between a Medical Necessity Guideline and a self-insured Member's benefit document, the provisions of the benefit document will govern. For Tufts Health Together (Medicaid), coverage may be available beyond these guidelines for pediatric members under age 21 under the Early and Periodic Screening, Diagnostic and Treatment (EPSDT) benefits of the plan in accordance with 130 CMR 450.140 and 130 CMR 447.000, and with prior authorization.

Treating providers are solely responsible for the medical advice and treatment of Members. The use of this guideline is not a guarantee of payment or a final prediction of how specific claim(s) will be adjudicated. Claims payment is subject to eligibility and benefits on the date of service, coordination of benefits, referral/authorization, utilization management guidelines when applicable, and adherence to plan policies, plan procedures, and claims editing logic.